Cargando…

Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy

OBJECTIVE: In the present study, the authors investigated the in vitro behavior of radio-resistant breast adenocarcinoma (MDA-MB-231) cells line and radiosensitive peripheral blood mononuclear cells (PBMC), as a function of different radiation doses, dose rates and postirradiation time kinetics, wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcão, Patrícia Lima, Motta, Bárbara Miranda, de Lima, Fernanda Castro, Lima, Celso Vieira, Campos, Tarcísio Passos Ribeiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Radiologia e Diagnóstico por Imagem 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492568/
https://www.ncbi.nlm.nih.gov/pubmed/26185342
http://dx.doi.org/10.1590/0100-3984.2014.0022
_version_ 1782379784929542144
author Falcão, Patrícia Lima
Motta, Bárbara Miranda
de Lima, Fernanda Castro
Lima, Celso Vieira
Campos, Tarcísio Passos Ribeiro
author_facet Falcão, Patrícia Lima
Motta, Bárbara Miranda
de Lima, Fernanda Castro
Lima, Celso Vieira
Campos, Tarcísio Passos Ribeiro
author_sort Falcão, Patrícia Lima
collection PubMed
description OBJECTIVE: In the present study, the authors investigated the in vitro behavior of radio-resistant breast adenocarcinoma (MDA-MB-231) cells line and radiosensitive peripheral blood mononuclear cells (PBMC), as a function of different radiation doses, dose rates and postirradiation time kinetics, with a view to the interest of clinical radiotherapy. MATERIALS AND METHODS: The cells were irradiated with Co-60, at 2 and 10 Gy and two different exposure rates, 339.56 cGy.min(–1) and the other corresponding to one fourth of the standard dose rates, present over a 10-year period of cobalt therapy. Post-irradiation sampling was performed at pre-established kinetics of 24, 48 and 72 hours. The optical density response in viability assay was evaluated and a morphological analysis was performed. RESULTS: Radiosensitive PBMC showed decrease in viability at 2 Gy, and a more significant decrease at 10 Gy for both dose rates. MDAMB- 231 cells presented viability decrease only at higher dose and dose rate. The results showed MDA-MB-231 clone expansion at low dose rate after 48–72 hours post-radiation. CONCLUSION: Low dose rate shows a possible potential clinical impact involving decrease in management of radio-resistant and radiosensitive tumor cell lines in cobalt therapy for breast cancer.
format Online
Article
Text
id pubmed-4492568
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Colégio Brasileiro de Radiologia e Diagnóstico por Imagem
record_format MEDLINE/PubMed
spelling pubmed-44925682015-07-16 Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy Falcão, Patrícia Lima Motta, Bárbara Miranda de Lima, Fernanda Castro Lima, Celso Vieira Campos, Tarcísio Passos Ribeiro Radiol Bras Original Articles OBJECTIVE: In the present study, the authors investigated the in vitro behavior of radio-resistant breast adenocarcinoma (MDA-MB-231) cells line and radiosensitive peripheral blood mononuclear cells (PBMC), as a function of different radiation doses, dose rates and postirradiation time kinetics, with a view to the interest of clinical radiotherapy. MATERIALS AND METHODS: The cells were irradiated with Co-60, at 2 and 10 Gy and two different exposure rates, 339.56 cGy.min(–1) and the other corresponding to one fourth of the standard dose rates, present over a 10-year period of cobalt therapy. Post-irradiation sampling was performed at pre-established kinetics of 24, 48 and 72 hours. The optical density response in viability assay was evaluated and a morphological analysis was performed. RESULTS: Radiosensitive PBMC showed decrease in viability at 2 Gy, and a more significant decrease at 10 Gy for both dose rates. MDAMB- 231 cells presented viability decrease only at higher dose and dose rate. The results showed MDA-MB-231 clone expansion at low dose rate after 48–72 hours post-radiation. CONCLUSION: Low dose rate shows a possible potential clinical impact involving decrease in management of radio-resistant and radiosensitive tumor cell lines in cobalt therapy for breast cancer. Colégio Brasileiro de Radiologia e Diagnóstico por Imagem 2015 /pmc/articles/PMC4492568/ /pubmed/26185342 http://dx.doi.org/10.1590/0100-3984.2014.0022 Text en © Colégio Brasileiro de Radiologia e Diagnóstico por Imagem http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Falcão, Patrícia Lima
Motta, Bárbara Miranda
de Lima, Fernanda Castro
Lima, Celso Vieira
Campos, Tarcísio Passos Ribeiro
Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy
title Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy
title_full Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy
title_fullStr Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy
title_full_unstemmed Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy
title_short Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy
title_sort enhancement of viability of radiosensitive (pbmc) and resistant (mda-mb-231) clones in low-dose-rate cobalt-60 radiation therapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492568/
https://www.ncbi.nlm.nih.gov/pubmed/26185342
http://dx.doi.org/10.1590/0100-3984.2014.0022
work_keys_str_mv AT falcaopatricialima enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy
AT mottabarbaramiranda enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy
AT delimafernandacastro enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy
AT limacelsovieira enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy
AT campostarcisiopassosribeiro enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy